Metformin suppresses intestinal polyp growth in ApcMin/+ mice

Cancer Science

Volumn 99, Issue 11, 2008, Pages 2136-2141

  Tomimoto, Ayako ^a   Endo, Hiroki ^a   Sugiyama, Michiko ^a   Fujisawa, Toshio ^a   Hosono, Kunihiro ^a   Takahashi, Hirokazu ^a   Nakajima, Noriko ^b   Nagashima, Yoji ^a   Wada, Koichiro ^c   Nakagama, Hitoshi ^d   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BROXURIDINE; CYCLIN D1; CYCLINE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MYC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; GENE ACTIVATION; GENE EXPRESSION; GENE SYNTHESIS; GROWTH INHIBITION; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTESTINE POLYP; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL PROLIFERATION; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; IMMUNOHISTOCHEMISTRY; INTESTINAL POLYPS; METFORMIN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 55449124298     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00933.x     Document Type: Article

References (24)

1. Jemal A, Tiwari RC, Murray T et al. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoclassic in the mouse. Science 1990; 247: 322-4.
3. Corpet DE, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003; 12: 391-400.
4. Su LK, Kinzler KW, Vogelstein B et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992; 256: 668-70.
5. He TC, Sparks AB, Rago C et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-12.
6. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21.
7. Psaty BM, Furberg CD. COX-2 inhibitors - lessons in drug safety. N Engl J Med 2005; 352: 1133-5.
8. Witters LA. The blooming of the French lilac. J Clin Invest 2001; 108: 1105-7.
9. Shaw RJ, Lamia KA, Vasquez D et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-6.
10. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-74.
11. Carretero J, Medina PP, Blanco R et al. Dysfunctional AMPK activity, signaling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 2007; 26: 1616-25.
12. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006; 574: 63-71.
13. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006; 25: 6416-22.
14. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8: 179-83.
15. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol 2005; 17: 158-66.
16. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-73.
17. Bergheim I, Guo L, Davis MA et al. Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology 2006; 130: 2099-112.
18. Buzzai M, Jones RG, Amaravadi RK et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-52.
19. Zou MH, Kirkpatrick SS, Davis BJ et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. J Biol Chem 2004; 279: 43940-51.
20. Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing MJ. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: Relationship with patient survival. Gastroenterology 1997; 112: 46-54.
21. Oka H, Shiozaki H, Kobayashi K et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993; 53: 1696-701.
22. William HG, Dan HM, Britt-Marie L. The prognostic value of proliferation indices: A study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treatment 2000; 59: 113-23.
23. Yamada Y, Hata K, Hirose Y et al. Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc (Min/+) mice. Cancer Res 2002; 62: 6367-70.
24. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-4.